Login to Your Account

Amgen Starting Phase III Trials With Treatment For Bone Loss

By Randall Osborne

Wednesday, August 11, 2004
As promised, Amgen Inc. began dosing patients in two pivotal Phase III trials of AMG 162, its fully human monoclonal antibody designed to treat post-menopausal osteoporosis (PMO) and treatment-induced bone loss. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription